Teva’s Generic Evista Launch Remains On Hold During Patent Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
In second court-order delay, judge grants temporary restraining order, saying Lilly is likely to prevail in patent infringement trial.
You may also be interested in...
Limited Launch Of Teva’s Generic Evista Rejected By Court
Preliminary injunction blocks Teva’s launch; firm had planned to sell one million bottles in eight-month period.
Limited Launch Of Teva’s Generic Evista Rejected By Court
Preliminary injunction blocks Teva’s launch; firm had planned to sell one million bottles in eight-month period.
Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases
Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it